We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Evgen Pharma Plc | LSE:EVG | London | Ordinary Share | GB00BSVYN304 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.775 | 0.75 | 0.80 | 0.775 | 0.775 | 0.78 | 745,046 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 422k | -4.04M | -0.0147 | -0.52 | 2.12M |
Date | Subject | Author | Discuss |
---|---|---|---|
12/10/2022 08:09 | It's not really risen much from like 3.2 to 5.8. should be 10p by now hence why I keep buying at these low levels. | wololol | |
12/10/2022 08:07 | I know this has risen but, its way too cheap for the pipeline - worth next to nothing - could rerate significantly IMO .. | givmesunshine | |
12/10/2022 08:06 | Should test that 7.8p again today. Enjoy everyone, that's more than 30%. Regards, F911 | firestorm911 | |
12/10/2022 08:05 | Same added £4k worth. | wololol | |
12/10/2022 08:04 | I added chaps. Regards, F911 | firestorm911 | |
12/10/2022 08:02 | An update on breast cancer research too! Maybe they do read the emails from PI's.... :) GLA. | lovewinshatelosses | |
12/10/2022 07:23 | Amazing RNS. Feel sorry for folk who sold out yesterday. I'll be trying to buy more this morning. Another 100% rise possible today. Chucking the kitchen sink at this. | wololol | |
12/10/2022 07:18 | With this statement they have increased the size of the dartboard and made it an even bigger target that is now even more likely to attract major players to pounce and take full advantage of the future potential that is now becoming apparent. | clocktower | |
12/10/2022 07:16 | Good rns. Dr Huw Jones, Evgen CEO, commented: "We expect to have a very complete set of data regarding the performance of the new formulation of SFX-01 by H1 2023, as planned. This will generate more insight than ever into the way SFX-01 is handled in the bloodstream and how it interacts with the key molecular targets of interest in a wide range of diseases. "We already have promising pre-clinical data in glioblastoma as well as Orphan Disease status which we announced last year. Given the complexity of this disease, and the time and cost that goes into such clinical studies, we want to de-risk the programme as much as possible. Under advice from experts, we believe a stronger understanding of the potential direct impacts of SFX-01 in the brain tumour tissue itself will enable us to improve the trial design further and enhance the prospects of success. "In the meantime, we are also focussing on our new and significant partnership with Stalicla SA and are driving our breast cancer programme forward in collaboration with the Manchester Breast Centre. We continue to explore partnering opportunities in the context of a considerably longer cash runway, with the prospect of significant further non-dilutive cash inflows from our partners." Esp the last bit. We continue to explore partnering opportunities in the context of a considerably longer cash runway, with the prospect of significant further non-dilutive cash inflows from our partners." | manual dexterity | |
12/10/2022 07:06 | After that comprehensive update again today you would hope some director buys now. Come on huw put your money where your mouth is... | markth126 | |
11/10/2022 20:32 | sPraY meNoT | andymunchkin | |
11/10/2022 19:49 | Looking forward to tomorrow's presentation. Should see another super day. Consolidation today double digits reality tomorrow. | smraynot | |
11/10/2022 15:23 | kickingking, I hope the question was phrased as follows - " Is there any market sensitive information at this time, that prevents the company directors from purchasing EVG stock in the open market at this time" | clocktower | |
11/10/2022 13:57 | Lots of buys showing as sells | bs2304 | |
11/10/2022 13:39 | I've already submitted that question. Hopefully they will put it to them tomorrow. It is strange that they waited two days to do the presentation after yesterday's news. Maybe they will announce something else tomorrow morning before investor meet in the afternoon. I'll expect more buyers returning just before the close of play today. | kickingking | |
11/10/2022 13:33 | Strong support at 6p. Double bottom should push on from here | wololol | |
11/10/2022 13:04 | Will the directors be buying some stock today and before the presentation tomorrow? If not will they be asked the same question as last time and if so it will be interesting to hear their response. | clocktower | |
11/10/2022 12:14 | Last placing was much higher without the current deal. | manual dexterity | |
11/10/2022 12:09 | Good man. Cross Fingers. Us against evil envious people. The good always wins. I stated yesterday MMS will stop the party with a mark up. The Crew hates mark up. Regards, F911 | firestorm911 | |
11/10/2022 11:41 | Firestorm I elam expecting 9.11p by the end of the week. | wololol | |
11/10/2022 11:40 | Wait for the yanks to wake up today ..... | hairballradical | |
11/10/2022 10:45 | It seems that very few have been able to make profits from trading this today so far but if we get a late surge, like yesterday they may get there day trading rewards yet. | clocktower | |
11/10/2022 09:32 | Agree "clocktower" presentation tomorrow will see the next hike up to double digits. This morning is all about the market makers manipulating the share price to allow them to gather stock before the next rise. As always dyor but don't fall into the trap and follow the leemings.🚀 | smraynot | |
11/10/2022 09:30 | Looks like that I may get mine at 4.25p yet. | regandharry5 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions